Cargando…

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Detalles Bibliográficos
Autores principales:	Van Oekelen, Oliver, Gleason, Charles R., Agte, Sarita, Srivastava, Komal, Beach, Katherine F., Aleman, Adolfo, Kappes, Katerina, Mouhieddine, Tarek H., Wang, Bo, Chari, Ajai, Cordon-Cardo, Carlos, Krammer, Florian, Jagannath, Sundar, Simon, Viviana, Wajnberg, Ania, Parekh, Samir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238657/ https://www.ncbi.nlm.nih.gov/pubmed/34242572 http://dx.doi.org/10.1016/j.ccell.2021.06.014

Ejemplares similares

OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
por: Oekelen, Oliver Van, et al.
Publicado: (2021)

NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
por: Verina, Daniel, et al.
Publicado: (2021)

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
por: Kogan Zajdman, Ariel, et al.
Publicado: (2022)

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
por: Aleman, Adolfo, et al.
Publicado: (2022)

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
por: Aleman, Adolfo, et al.
Publicado: (2021)

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
por: Mouhieddine, Tarek H., et al.
Publicado: (2022)

MM-239: A Tertiary Center Experience of Multiple Myeloma Patients with COVID-19: Lessons Learned and the Path Forward
por: Wang, Bo, et al.
Publicado: (2020)

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
por: Wang, Bo, et al.
Publicado: (2020)

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
por: Wang, Bo, et al.
Publicado: (2020)

NS-64: Lessons learned: patient management and outcomes of Multiple Myeloma patients during the COVID-19 pandemic in New York City
por: Catamero, Donna, et al.
Publicado: (2021)

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
por: Elnaggar, Muhammad, et al.
Publicado: (2022)

Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
por: Elnaggar, Muhammad, et al.
Publicado: (2023)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
por: Singh, Gagandeep, et al.
Publicado: (2023)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

P876: INCIDENTAL DISCOVERY OF PROBABLE PATHOGENIC GERMLINE VARIANTS IN MULTIPLE MYELOMA PATIENTS UNDERGOING SOMATIC GENOMIC PROFILING
por: Thibaud, S., et al.
Publicado: (2022)

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
por: Lancman, Guido, et al.
Publicado: (2018)

COVID-19: Staging of a New Disease
por: Cordon-Cardo, Carlos, et al.
Publicado: (2020)

SARS-CoV-2 viral load predicts COVID-19 mortality
por: Pujadas, Elisabet, et al.
Publicado: (2020)

Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
por: Wajnberg, Ania, et al.
Publicado: (2020)

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
por: Wajnberg, Ania, et al.
Publicado: (2020)

Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
por: Bhalla, Sherry, et al.
Publicado: (2021)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants
por: Kubale, John, et al.
Publicado: (2022)

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21(Cip1)
por: Mei, Anna Huo-Chang, et al.
Publicado: (2020)

CD8(+) T cells: An ineffective armor against prolonged COVID-19 in cancer patients
por: Van Oekelen, Oliver, et al.
Publicado: (2022)

Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies
por: Żak, Magdalena M., et al.
Publicado: (2021)

At the Crossroads of Inflammation and Tumorigenesis
por: Cordon-Cardo, Carlos, et al.
Publicado: (1999)

Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays
por: Aleman, A, et al.
Publicado: (2008)

Applications of array technology: identification of molecular targets in bladder cancer
por: Sánchez-Carbayo, M, et al.
Publicado: (2003)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
por: Chari, Ajai, et al.
Publicado: (2014)

Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
por: Laganà, Alessandro, et al.
Publicado: (2018)

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
por: Martin, Thomas G., et al.
Publicado: (2021)

SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals
por: Sano, Kaori, et al.
Publicado: (2022)

Communication Gap in ICU: SPIKES Can Be a Useful Tool!
por: Govindasaami, Vinod, et al.
Publicado: (2023)

Demographic Characteristics of Adults with IgG Antibodies to Prior Symptomatic SARS-CoV-2 Infection
por: Mansour, Mayce, et al.
Publicado: (2021)

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
por: Theodoropoulos, Nicholas, et al.
Publicado: (2020)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r2itmnuhn56vhkc9q0bmvj5rht